Navigation Links
Cephalon Announces FDA Approval of Risk Evaluation and Mitigation Strategies for NUVIGIL and PROVIGIL
Date:10/22/2010

e at www.provigil.com.

About Cephalon, Inc.Cephalon is a global biopharmaceutical company dedicated to discovering, developing and bringing to market medications to improve the quality of life of individuals around the world.  Since its inception in 1987, Cephalon has brought first-in-class and best-in-class medicines to patients in several therapeutic areas.  Cephalon has the distinction of being one of the world's fastest-growing biopharmaceutical companies, now among the Fortune 1000 and a member of the S&P 500 Index, employing approximately 4,000 people worldwide.  The company sells numerous branded and generic products around the world.  In total, Cephalon sells more than 150 products in nearly 100 countries.  More information on Cephalon and its products is available at www.cephalon.com.

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide the Cephalon current expectations or forecasts of future events.  These may include statements regarding anticipated scientific progress on its research programs; development of potential pharmaceutical products; interpretation of clinical results; prospects for regulatory approval; manufacturing development and capabilities; market prospects for its products; and other statements regarding matters that are not historical facts.  You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceu
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkins Lymphoma
3. Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkins Lymphoma
4. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
5. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
6. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
7. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
8. Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
9. Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
10. Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder
11. Cephalon Signs Option Agreement to Acquire BioAssets Development Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014  Iliad Neurosciences, Inc., a ... diagnosing and treating Autism Spectrum Disorders (ASD) announced today ... with The Research Foundation for The State University of ... provide a new biomarker to identify an abnormality in ... ASD. This biomarker is expected to be available for ...
(Date:9/18/2014)... , Sept. 18, 2014  ePharmaSolutions, ... was recognized as the Disruptive Innovator of ... ePharmaONE cloud-based eClinical platform. This solution includes ... trial master file (eTMF), a remote monitoring ... ePharmaSolutions, ReferralPlus+ patient screening and matching technology. ...
(Date:9/18/2014)... PLAINSBORO, N.J. , Sept. 18, ... of the National Hemophilia Foundation,s (NHF) new three-year ... support to people with hemophilia and their families/caregivers ... that can impede disease management. The curriculum for ... With Your Provider About Pain , focuses on ...
Breaking Medicine Technology:Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 2Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 3ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 2ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 3Novo Nordisk Supports National Hemophilia Foundation Initiative for "Collaborating in Care" Disease Management Program 2Novo Nordisk Supports National Hemophilia Foundation Initiative for "Collaborating in Care" Disease Management Program 3
... 1 RX-3341 Results -, NEW HAVEN, Conn., ... "Company"), a development-stage company focused on the,discovery and ... infections, today announced the initiation of a Phase,2 ... compound RX-3341 in,the treatment of complicated skin and ...
... Will Remain as the Clinical Gold Standard ... New Report from Decision Resources, WALTHAM, Mass., ... leading research and advisory firms focusing on pharmaceutical ... in preventing,recurrence of depressive mood episodes in patients ...
Cached Medicine Technology:Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections 2Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections 3Current and Emerging Drugs Continue to Struggle for Patient Share in the Treatment of Major Depressive Disorder 2
(Date:9/19/2014)... 19, 2014 VogueQueen.com has ... that will make ladies more beautiful at their weddings. ... everyone can afford. The company’s new products are made ... offering great savings for all the global clients. ... extremely beautiful. I have ordered several items on its ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Defendants ... http://www.xareltolawsuitcenter.com ) currently pending in Pennsylvania’s Philadelphia Court ... claims filed on behalf of out-of-state plaintiffs dismissed, ... on September 11th, the defendants maintain that circumstances ... in the lawsuits have no connection to Pennsylvania. ...
(Date:9/18/2014)... 2014 Dr. David A. F. Ellis ... American Academy of Facial Plastic and Reconstructive Surgery and ... Division of Facial Plastic Surgery. He is recognized ... surgery. , Dr. Ellis will be presenting on ... presenting on injection techniques and various treatments for complications ...
(Date:9/18/2014)... to diverse communities may boost infants, social learning, according ... in the park or supermarket could help children be ... different from them, researchers found. "Research has ... interacting with and learning from people who are different ... psychology professor, said in a university news release. ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 "Medical staff ... care while also maintaining the patient's privacy," said one ... with this idea in order to supply caregivers with ... , They created a prototype for The Helper to ... enables staff to turn patient onto his or her ...
Breaking Medicine News(10 mins):Health News:VogueQueen.com’s New Line Of Cheap Wedding Dresses Aims To Attract Chic Ladies 2Health News:Xarelto Lawsuit Defendants Seek to Have Pennsylvania Claims Filed by Out-of-State Plaintiffs Dismissed, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Defendants Seek to Have Pennsylvania Claims Filed by Out-of-State Plaintiffs Dismissed, Bernstein Liebhard LLP Reports 3Health News:Dr. David A. F. Ellis Has Been Invited to Speak at a Conference of the American Academy of Facial Plastic and Reconstructive Surgery in Orlando, Florida 2Health News:Study: Exposure to Diversity Might Boost Baby's Social Skills 2
... , RE: American Psychological Association 116th Annual Convention in ... 162A, Meeting Level 1, Boston Convention and Exhibition Center. ... tops and two high-speed printers. We will also provide ... transmission and APA staff resources. This room will also ...
... Joel Ario today announced that the Insurance Department ... the state to,hear from consumers and other affected ... and Independence Blue Cross, plus related,changes, will impact ... held July 8 in Pittsburgh, July 10 in ...
... Officials Not to Privatize,Veterans, Health Care, WASHINGTON, ... today launched a nationwide radio ad campaign,urging Congress ... of,Veterans, Affairs. In the ad, AFGE urges presidential ... for the VA., "As the nation,s highest ...
... release is available in French . , Montreal, ... traumatic experience and, in some cases, emotional and physical pain ... phantom limb syndrome, Universit de Montral graduate student Emma Duerden ... for a major study. , Our main goal is to ...
... of cancers that affect tissues such as muscle, fat, ... Italy on 13-14 May to discuss the latest information ... for therapy. , The 2nd Symposium on Sarcoma and ... for Medical Oncology (ESMO), will include sessions on the ...
... International Inc., found to have committed patent and ... ... Mannatech,Incorporated (Nasdaq: MTEX ) a leading developer and provider ... federal court,jury in the Northern District of Texas found that ...
Cached Medicine News:Health News:Highlights for APA's 116th Annual Convention in Boston, Aug. 14-17 2Health News:Highlights for APA's 116th Annual Convention in Boston, Aug. 14-17 3Health News:Highlights for APA's 116th Annual Convention in Boston, Aug. 14-17 4Health News:Insurance Department to Hold Statewide Meetings on Proposed Consolidation of Independence Blue Cross, Highmark 2Health News:AFGE Launches Nationwide Ad Campaign Aimed at Funding the VA 2Health News:2nd ESMO symposium on soft tissue carcinomas and GIST 2Health News:2nd ESMO symposium on soft tissue carcinomas and GIST 3Health News:Jury Validates Key Mannatech Technology Patents Involving Its Ambrotose(R) Glyconutrient Products 2Health News:Jury Validates Key Mannatech Technology Patents Involving Its Ambrotose(R) Glyconutrient Products 3
... This functional brace is designed for the ... and fibula. The preformed design provides post ... removal of internal or external fixation. The ... and below the fracture site, increasing vascularity ...
... Brace features a multi-axial hinge that duplicates ... altering kinematics. The infinite degree of adjustment ... and extension control of the knee. , ... tibia in correct anatomical alignment. The precision ...
... is a revolutionary cast replacement system for ... leg and foot. , ,A self-adjusting ... and in conjunction with a rigid lattice ... time of fracture or rupture healing can ...
... the constant demands of mobilizing patients quickly. ... necessary to fit bilateral KAFO's.,The complete kit ... knee joints , 4 Copolymer thigh support ... bands , Ortho-wick™ Padding for thigh , ...
Medicine Products: